消痰解郁方可以改善DC并发抑郁患者的临床症状和免疫功能，提高生存质量，降低抑郁量表评分，临床使用安全有效。
XTJYP can improve the clinical symptoms and immune function of the patients with DC concurrent depression, improve the quality of life and reduce depression scales' score, it's safe and effective.
将食管癌兼有抑郁症状的病人随机分为治疗组和对照组，治疗组采用疏肝解郁中药与活血化瘀药交替口服，观察两组抑郁量表评分的变化与局控率、生存率的变化。
Group A was treated with traditional chinese medicine, group B was control one . Changes of SDS scores, local control rate and survival rate were achieved in the two groups.
方法：采用多种量表评分对114例卒中后抑郁患者进行随机、对照并随访1年的前瞻性研究。
Methods:A controlled prospective design was applied in this study of 114 patients with depression after stroke. Several scales were used for functional measure.
所有患者均常规行汉密尔顿抑郁量表（HAMD）评分，根据头颅MRI结果分析病变部位。
The patients had been regularly tested by the Hamilton Depression Rating Scale for Depression(HAMD), the lesion location was analyzed by MRI.
结果：经多元逐步回归分析，进入回归方程的变量依次为日常生活能力量表评分、卒中次数、婚姻状况、陪护情况、抑郁自评量表评分。
Results: Five independent variables had been put into regression equation by multiple regression analysis, which were ADL score, stroke attack time, marriage, carer and SDS score.
评价在8周的时间内汉密尔顿抑郁量及帕金森病运动功能评分量表（MDRSPD）评分的变化。
The primary outcomes were the change in the Hamilton Depression Rating Scale(HAM-D) and motor dysfunction rating scale for Parkinson's disease(MDRSPD) in 8 weeks.
结果两组抑郁自评量表（SDS）、焦虑自评量表（SAS）、社交回避及苦恼量表（SAD）、症状自评量表（SCL-90）因子评分（除偏执、精神病性外）比较，差异有统计学意义（均P<0.05）。
Results The scores of SDS, SAS, SAD, and SCL-90 except the factors of paranoid ideation and psychoticism showed significant differences between the two groups(P<0.05 for all).
结果两组抑郁自评量表（SDS）、焦虑自评量表（SAS）、社交回避及苦恼量表（SAD）、症状自评量表（SCL-90）因子评分（除偏执、精神病性外）比较，差异有统计学意义（均P<0.05）。
Results The scores of SDS, SAS, SAD, and SCL-90 except the factors of paranoid ideation and psychoticism showed significant differences between the two groups(P<0.05 for all).
应用推荐